Germany approves third trial of COVID-19 vaccine candidate


  • World
  • Friday, 02 Oct 2020

FILE PHOTO: A June 24, 2020 handout photo received from biotech company IDT Biologika in Dessau-Rosslau, Germany, on July 28, 2020, shows an individual dose of the filled SARS-CoV-2 vaccine candidate. Hartmut Boesener/IDT Biologika/Handout via Reuters

BERLIN (Reuters) - Unlisted biotech firm IDT Biologika has won approval from Germany's vaccine regulator to become the third German company after BioNTech and CureVac to launch human trials of an experimental coronavirus vaccine in the country.

The trial of the vaccine, which has been developed with the German Centre for Infection Research (DZIF), will be conducted on 30 participants aged between 18 and 55 who will receive two vaccinations at four-week intervals.

Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In World

Colombia to buy Saab fighter aircraft, Swedish public radio reports
Nigeria court frees 119 protesters after government drops charges
Greek court detains man pending trial over Athens apartment blast
Greece mulls migrant facility on Rhodes to tackle rise in arrivals
German liberals bat away Greens' peace offering on coalition
Spain earmarks 10.6 billion euros in loans, grants to flood victims
Polls open in US as millions prepare to vote
Bluetongue virus threatens Sardinia's historic sheep farming industry
G7 and allies warn Russia over use of North Korean troops in Ukraine
Russian missile kills six, injures 20 in Ukraine's Zaporizhzhia

Others Also Read